SYRE

SEC source: 0001140361-17-045127 · doc1.xml · nonDerivative · entry 3

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,121

F3 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.70 to $5.10 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001140361-17-045129 · doc1.xml · nonDerivative · entry 6

York Charles N II · CIK 0001655962 · Chief Financial Officer and VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,787

F4 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.69 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001140361-17-045127 · doc1.xml · nonDerivative · entry 2

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,056

F2 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.85 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001140361-17-045129 · doc1.xml · nonDerivative · entry 5

York Charles N II · CIK 0001655962 · Chief Financial Officer and VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,546

F3 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.84 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001140361-17-045123 · doc1.xml · derivative · entry 1

GEORGIOU GEORGE · CIK 0000749811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-11-30

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001140361-17-045128 · doc1.xml · derivative · entry 1

Shanafelt Armen · CIK 0001656151 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-11-30

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001140361-17-045125 · doc1.xml · derivative · entry 1

Mahatme Sandesh · CIK 0001511034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-11-30

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001140361-17-045121 · doc1.xml · derivative · entry 1

Cox Russell J. · CIK 0001512984 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-11-30

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001140361-17-045127 · doc1.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,100

F1 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.29 to $4.60 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001140361-17-045129 · doc1.xml · nonDerivative · entry 4

York Charles N II · CIK 0001655962 · Chief Financial Officer and VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,287

F2 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.48 to $4.65 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001140361-17-034179 · doc1.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · Interim CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2027-08-30

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 100% of the shares subject to the option on July 18, 2018, subject to the continuing service of the Reporting Person on the vesting date.

SEC source: 0001140361-17-033209 · doc1.xml · derivative · entry 2

Wooldridge James · CIK 0001710641 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2027-08-21

F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 50% of the shares subject to the option on August 22, 2018, an additional 30% of the shares subject to the option on August 22, 2019, and the remaining 20% of the shares subject to the option on August 22, 2020, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-033209 · doc1.xml · derivative · entry 1

Wooldridge James · CIK 0001710641 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,000

Underlying: Common Stock · 165,000 shares

Expires 2027-08-21

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/4th of the shares subject to the option on July 10, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-033207 · doc1.xml · derivative · entry 1

Schuchart Aaron · CIK 0001709258 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2027-08-21

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 50% of the shares subject to the option on August 22, 2018, an additional 30% of the shares subject to the option on August 22, 2019, and the remaining 20% of the shares subject to the option on August 22, 2020, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-033208 · doc1.xml · derivative · entry 1

TYLER JOSEPH E · CIK 0001212744 · VP, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-08-21

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 50% of the shares subject to the option on August 22, 2018, an additional 30% of the shares subject to the option on August 22, 2019, and the remaining 20% of the shares subject to the option on August 22, 2020, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-033210 · doc1.xml · derivative · entry 1

York Charles N II · CIK 0001655962 · Chief Financial Officer and VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,500

Underlying: Common Stock · 58,500 shares

Expires 2027-08-21

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 50% of the shares subject to the option on August 22, 2018, an additional 30% of the shares subject to the option on August 22, 2019, and the remaining 20% of the shares subject to the option on August 22, 2020, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-033206 · doc1.xml · derivative · entry 1

Rowlinson Scott W · CIK 0001655979 · VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-08-21

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 50% of the shares subject to the option on August 22, 2018, an additional 30% of the shares subject to the option on August 22, 2019, and the remaining 20% of the shares subject to the option on August 22, 2020, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-045129 · doc1.xml · nonDerivative · entry 3

York Charles N II · CIK 0001655962 · Chief Financial Officer and VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,787

F1 · shares: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-17-025613 · doc1.xml · derivative · entry 1

Schuchart Aaron · CIK 0001709258 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2027-06-15

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/4th of the shares subject to the option on May 22, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-016748 · doc1.xml · derivative · entry 1

Quinn Anthony · CIK 0001532219 · Director · interim Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2027-04-20

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three equal monthly installments beginning on May 21, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-012946 · doc1.xml · derivative · entry 1

Hebel Henry · CIK 0001670189 · VP, Product Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,200

Underlying: Common Stock · 38,200 shares

Expires 2027-03-19

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-012950 · doc1.xml · derivative · entry 1

TYLER JOSEPH E · CIK 0001212744 · VP, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,000

Underlying: Common Stock · 39,000 shares

Expires 2027-03-19

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-012947 · doc1.xml · derivative · entry 1

Lowe David George · CIK 0001392094 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2027-03-19

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-012952 · doc1.xml · derivative · entry 1

York Charles N II · CIK 0001655962 · Chief Financial Officer and VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2027-03-19

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0001140361-17-012949 · doc1.xml · derivative · entry 1

Rowlinson Scott W · CIK 0001655979 · VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2027-03-19

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

SEC source: 0000947871-17-000160 · ss31932_4.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · 10% owner

ISALY SAMUEL D · CIK 0001055949 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,469,524

F3 · price: The price reported in Column 4 is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $5.25 to $5.50 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.

F4 · ownership.nature: These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F5 · ownership.nature: This report on Form 4 is jointly filed by GP V, Advisors, and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-17-000160 · ss31932_4.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · 10% owner

ISALY SAMUEL D · CIK 0001055949 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,462,524

F2 · price: The price reported in Column 4 is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.

F4 · ownership.nature: These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F5 · ownership.nature: This report on Form 4 is jointly filed by GP V, Advisors, and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-17-000160 · ss31932_4.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · 10% owner

ISALY SAMUEL D · CIK 0001055949 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,390,724

F1 · price: The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were purchased in multiple transactions at prices ranging from $4.97 to $5.10 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the "SEC") full information regarding the Shares purchased at each separate price within the range set forth in this footnote.

F4 · ownership.nature: These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F5 · ownership.nature: This report on Form 4 is jointly filed by GP V, Advisors, and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001140361-17-007979 · doc1.xml · derivative · entry 1

Bruhn Suzanne Louise · CIK 0001517790 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,000

Underlying: Common Stock · 82,000 shares

Expires 2027-02-14

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 36 equal monthly installments beginning on March 15, 2017, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001140361-17-045129 · doc1.xml · nonDerivative · entry 2

York Charles N II · CIK 0001655962 · Chief Financial Officer and VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,828

F1 · shares: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-17-045129 · doc1.xml · nonDerivative · entry 1

York Charles N II · CIK 0001655962 · Chief Financial Officer and VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,828

F1 · shares: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0000059478-16-000339 · wf-form4_146067370280526.xml · derivative · entry 4

LILLY ELI & CO · CIK 0000059478 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · by fund

Disclosed balance after: 0

Underlying: Common Stock · 1,120,448 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.

F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.

F2 · ownership.nature: These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.

SEC source: 0000059478-16-000339 · wf-form4_146067370280526.xml · derivative · entry 3

LILLY ELI & CO · CIK 0000059478 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · by fund

Disclosed balance after: 0

Underlying: Common Stock · 890,476 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.

F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.

F2 · ownership.nature: These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.

SEC source: 0000059478-16-000339 · wf-form4_146067370280526.xml · nonDerivative · entry 2

LILLY ELI & CO · CIK 0000059478 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · by fund

Disclosed balance after: 2,568,543

F2 · ownership.nature: These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.

SEC source: 0000059478-16-000339 · wf-form4_146067370280526.xml · nonDerivative · entry 1

LILLY ELI & CO · CIK 0000059478 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · by fund

Disclosed balance after: 2,068,543

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.

F2 · ownership.nature: These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.

SEC source: 0000059478-16-000342 · wf-form4a_146067689367014.xml · nonDerivative · entry 1

LILLY ELI & CO · CIK 0000059478 · 10% owner

Lilly Ventures Fund I LLC · CIK 0001575852 · 10% owner

Shanafelt Armen · CIK 0001656151 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · by fund

Disclosed balance after: 2,068,543

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.

F2 · ownership.nature: These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.

F3 · ownership.nature: This line item is being re-reported in order to gain access to the filing system. This Form is being amended to include Reporting Owners, Lilly Ventures Fund I LLC, and Dr. Shanafelt Armen as beneficial owners of the shares reported in the Form 4, previously filed by Eli Lilly and Company on April 14, 2016.